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Abstract
Introduction: Adiponectin is a peptide secreted by adipocytes; its reduction is associated with obesity-related disorders, including insulin 
resistance (IR). The study analysed levels of total adiponectin and its high-molecular-weight (HMW) oligomer in a group of metabolically 
healthy adults and in patients with type 2 diabetes mellitus (T2DM) to evaluate these levels as potential predictors of the presence of IR.
Materials and methods: The study comprised 269 metabolically healthy adults and 300 patients with T2DM. Anthropometric and bio-
chemical indices were measured, including total and HMW adiponectin levels; the Homeostatic Model Assessment of IR (HOMA-IR) 
index was calculated, and logistic regression analysis was used to predict the presence of IR. 
Results: In healthy individuals, both total and HMW adiponectin levels were significantly higher than in diabetic patients. Total and HMW 
adiponectin levels were moderately correlated with the HOMA-IR index. Logistic regression analysis showed that increased levels of both 
total adiponectin (odds ratio [OR] 0.598, 95% confidence interval [CI] 0.483–0.723) and the HMW form (OR 0.360, 95% CI 0.242–0.511) are 
protective factors for the development of IR. The cut-off levels were 4.22 mg/L for total adiponectin and 2.75 mg/L for HMW adiponectin. 
The results are valid for middle-aged European adults. 
Conclusions: Adiponectin levels below the indicated cut-offs may predict a potential risk for the development of IR. (Endokrynol Pol 
2018; 69 (4): 375–380)
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Streszczenie
Wstęp: Adiponektyna jest peptydem wydzielanym przez adipocyty, na zmniejszenie jej wydzielania mają wpływ choroby związane 
z otyłością, w tym insulinooporność (insulin resistance; IR). W badaniu poddano analizie stężenia adiponektyny całkowitej i jej wysoko-
cząsteczkowego (high-molecular-weight; HMW) oligomeru w grupie metabolicznie zdrowych dorosłych oraz pacjentów z cukrzycą typu 2 
(type 2 diabetes mellitus; T2DM). Stężenia te oceniano jako potencjalne czynniki predykcyjne obecności insulinooporności.
Materiał i metody: W badaniu wzięło udział 269 zdrowych pod względem metabolicznym dorosłych i 300 pacjentów z cukrzycą typu 
2. Aby przewidzieć obecność insulinooporności, zmierzono wskaźniki antropometryczne i biochemiczne, w tym stężenia adiponektyny 
całkowitej i jej wysokocząsteczkowej frakcji, skalkulowano homeostatyczny model oceny insulinooporności (HOMA-IR) oraz zastosowano 
analizę regresji logistycznej. 
Wyniki: Stężenia adiponektyny całkowitej i jej wysokocząsteczkowej frakcji były znacząco wyższe u osób zdrowych niż u pacjentów 
cukrzycowych. Były one również umiarkowanie skorelowane ze wskaźnikiem HOMA-IR. Analiza regresji logistycznej wykazała, że 
podwyższone stężenia zarówno całkowitej adiponektyny (iloraz szans [odds ratio; OR] 0,598, 95% przedział ufności [confidence interval; CI] 
0,483–0,723), jak i wysokocząsteczkowej frakcji (OR 0,360, 95% CI 0,242–0,511) są czynnikami ochronnymi przed rozwojem insulinoopor-
ności. Stężenie graniczne dla całkowitej adiponektyny wynosiłi 4,22 mg/l, natomiast dla frakcji wysokocząsteczkowej 2,75 mg/l. Wyniki 
są zasadne dla dorosłych Europejczyków w średnim wieku.
Wnioski: Stężenia adiponektyny poniżej wskazanych poziomów granicznych mogą przewidywać potencjalne ryzyko rozwoju insulinoopor-
ności. (Endokrynol Pol 2018; 69 (4): 375–380)
Słowa kluczowe: adiponektyna całkowita, adiponektyna wysokocząsteczkowa, insulinooporność, iloraz szans, przewidywania, punkty graniczne
Introduction
Adiponectin, a protein produced by adipocytes, plays 
an important role in the metabolism of glucose and 
lipids. It is a key component in the interrelationship 
between adiposity, insulin resistance (IR), and inflam-
mation [1]. Concentrations of total adiponectin decrease 
in association with the development of metabolic dys-
function such as obesity, IR, or type 2 diabetes mellitus 
(T2DM) [2]. However, it has been suggested that obesity 
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may not be an independent factor affecting plasma 
adiponectin level, and that an obesity-related decrease 
in plasma adipokine levels may be a consequence of 
obesity-related metabolic disorders [3]. 
The discovery of adiponectin seems to be an important 
landmark in the study of obesity and the related meta-
bolic dysfunction accompanied by IR. In metabolically 
healthy individuals, adiponectin circulates at relatively 
high concentrations and is readily quantified by avail-
able laboratory methods [4]. Adiponectin circulates in 
human serum as high-molecular-weight (HMW) and 
low-molecular-weight (LMW) oligomers. The ratio of 
the HMW form to the total adiponectin level is referred 
to as the adiponectin sensitivity index [5]. 
Adiponectin is involved in regulation of lipid and 
glucose metabolism. Increased fatty acid oxidation 
in skeletal muscles may be the basis of the insulin-
sensitising effect of adiponectin. Studies have revealed 
that adiponectin enhances triglyceride catabolism, fatty 
acid uptake, and mitochondrial biogenesis, demonstrat-
ing the importance of adiponectin in regulating lipid 
metabolism in skeletal muscles. Decreased adiponectin 
concentrations have been linked to higher low-density 
lipoprotein (LDL) cholesterol and triglyceride concen-
trations, probably due to a direct effect of adiponectin 
on lipoprotein lipase activity [2].
Concentrations of adiponectin and its HMW form 
have been extensively evaluated as epidemiological 
markers of the risk for developing IR, T2DM, or meta-
bolic syndrome [6]. Adiponectin levels are very well 
correlated with the Homeostatic Model Assessment of 
IR (HOMA-IR) index in adults [7]. The adiponectin sen-
sitivity index may be a useful parameter, in combination 
with others such as the oral glucose tolerance test, for 
a comprehensive assessment of IR [8]. Adiponectin has 
been proposed as a potential prognostic biomarker and 
a therapeutic target in patients with cardiometabolic 
diseases [9]. The present study aimed at assessing the 
potential use of decreased total and HMW adiponectin 
levels for predicting the presence of IR in middle-aged 
adults. Another aim was to specify the cut-off points 
signalling the development of IR.
Material and methods
Patients and samples
Data for the study were collected from January 2011 
to April 2013. The study was approved by the institu-
tional Ethics Committee, and informed consent was 
obtained from all participants. Two groups of subjects 
were enrolled. Group A (controls) comprised healthy 
individuals with no clinical or biochemical markers 
of metabolic disease. Group B (cases) consisted of pa-
tients with T2DM treated with oral antidiabetic drugs, 
most frequently metformin. Healthy controls were 
recruited at the Department of Exercise Medicine and 
Cardiovascular Rehabilitation, University Hospital Olo-
mouc, and Blood Transfusion Department, University 
Hospital Olomouc. Diabetic patients were recruited 
at a diabetes outpatient centre of the Department of 
Internal Medicine, University Hospital Ostrava. Labo-
ratory analyses were carried out at the Department of 
Clinical Biochemistry, University Hospital Olomouc. In 
all participants, waist circumference, body height and 
weight for body mass index (BMI) calculations, and 
blood pressure were measured. After 12-hour fasting, 
venous blood was collected.
Laboratory analysis 
Venous blood samples were drawn in the morning af-
ter a 12-hour fast. After centrifugation, the serum was 
used for other analyses. Routine serum biochemical 
parameters were analysed on a Modular SWA (Roche, 
Basel, Switzerland) on the day of blood collection. 
Concentrations of adipokines and other special ana-
lytes were measured in sample aliquots stored at –80 
(–20)°C for no longer than six months (see below). Total 
cholesterol, triglycerides and high-density lipoprotein 
(HDL) cholesterol were determined enzymatically on 
the above analyser. Concentrations of apolipoprotein 
B (ApoB) and ApoA1 were determined immunoturbi-
dimetrically using Tina-quant ApoB and ApoA1 kits 
(Roche). C-reactive protein (CRP) was assessed by an 
ultrasensitive immunoturbidimetric method using 
the Tina-quant kit. Glucose was determined using the 
GOD-PAP method (Roche). All tests were performed 
using fresh sera on the day of blood collection. Insulin 
was determined by the IRMA method using a com-
mercially available kit (Immunotech, Marseille, France) 
and specific antibodies. Total adiponectin (one separate 
aliquot stored at –80°C until the day of analysis) was 
determined with the Human Adiponectin ELISA im-
munochemical kits (Biovendor Laboratory Medicine, 
Brno, Czech Republic) according to the manufacturer’s 
instructions and after verification of methods. HMW 
adiponectin was determined from the same aliquot by 
ELISA using the HMW Adiponectin ELISA Kit (Otsuka 
Pharmaceutical, Tokyo, Japan).
Statistical analysis 
Statistical analysis was performed using the computing 
environment R (R Foundation for Statistical Comput-
ing, Austria; http://www.r-project.org/). Data were pre-
sented as basic robust (median) and non-robust (mean, 
standard deviation) summary characteristics (Table I). 
The Shapiro-Wilk test was used to test normality. Be-
cause the metabolic parameters showed deviations from 
the normal distribution, Spearman’s rank correlation 
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coefficient was used. Monotonic dependence of total 
adiponectin or HMW adiponectin on the HOMA-IR 
index, insulin and glucose was quantified using Spear-
man’s rank correlation coefficient (r); at the same time, 
its significant difference from zero was tested (Table II). 
We verbally describe the strength of the correlation 
using the guide that Evans (1996) suggests for the ab-
solute value of r: 0.00–0.19 very weak, 0.20–0.39 weak, 
0.40–0.59 moderate, 0.60–0.79 strong, and 0.80–1.00 very 
strong [10]. The correlations were depicted as scatter 
diagrams. Logistic regression analysis with continu-
ous predictors for IR prediction was used (Table III). 
Table I. Basic metabolic and clinical characteristics of subjects
Tabela I. Podstawowe cechy metaboliczne i kliniczne pacjentów
Characteristics Healthy (Group A) 
mean ± SD (median)
T2DM (Group B) 
mean ± SD (median)
N 269 (F143, M126) 300 (F175, M125)
Age (years) 57.5 ± 10.6 59.8 ± 11.2
BMI [kg/m²] 24.9 ± 1.8 (25.3) 33.6 ± 5.6 (30.8)*
Waist [cm] 76.2 ± 10.3 (80) 112.7 ± 9.3 (108)
BP systolic [mmHg] 123.1 ± 10.5 (120) 145.2 ± 8.6 (143)*
BP diastolic [mmHg] 76.8 ± 7.1 (80) 84.7 ± 10.9 (85)*
Total cholesterol [mmol/L] 4.96 ± 0.8 (4.94) 5.60 ± 1.02 (4.9)*
Triglycerides [mmol/L] 1.34 ± 0.6 (1.06) 2.08 ± 1.03 (1.8)*
HDL cholesterol [mmol/L] 1.51 ± 0.41 (1.45) 1.26 ± 0.32 (1.23)*
LDL cholesterol [mmol/L] 2.84 ± 0.78 (2.79) 3.09 ± 0.88 (3.03)*
Glucose [mmol/L] 5.20 ± 0.6 (5.0) 8.40 ± 1.8 (8.31)*
Insulin [mIU/L] 10.18 ± 2.3 (6.5) 14.78 ± 10.6 (11.4)*
ApoA1 [g/L] 1.61 ± 0.2 (1.56) 1.23 ± 0.25 (1.18)*
ApoB [g/L] 0.80 ± 0.2 (0.85) 0.94 ± 0.23 (0.91)*
CRP [mg/L] 0.77 ± 0.34 (0.68) 2.85 ± 0.4 (2.67)*
Total adiponectin [mg/L] 10.6 ± 3.6 (8.6) 5.1 ± 1.5 (4.1)*
HMW adiponectin [mg/L] 5.2 ± 1.3 (4.8) 2.9 ± 0.9 (2.8)*
HMW/total adiponectin ratio 0.49 ± 0.07 0.56 ± 0.05*
HOMA-IR 2.49 ± 3.57 5.43 ± 3.2*
*P < 0.001 (comparison with healthy subjects)
SD, standard deviation; M, male; F, female; BP, blood pressure
HOMA-IR = fasting insulin [µIU/mL] x fasting glucose [mmol/L] / 22.5
Table II. Spearman’s rank correlation coefficient (r) between 
total adiponectin or HMW adiponectin and the variables 
(HOMA-IR, insulin, glucose)
Tabela II. Współczynnik korelacji rang Spearmana (r) 
między adiponektyną całkowitą lub wysokocząsteczkową 
a zmiennymi (wskaźnik HOMA-IR, insulina, glukoza)
Total adiponectin  HMW adiponectin
HOMA-IR –0.44 –0.41
Insulin –0.39 –0.33
Glucose –0.31 –0.29
P < 0.001
Table III. Binary logistic regression of IR risk factors, gender adjusted
Tabela III. Binarna regresja logistyczna czynników ryzyka insulinooporności z uwzględnieniem płci
β estimate SE Wald P-value OR 95% CI
Total adiponectin –0.515 0.103 –4.985 < 0.001 0.598 0.483–0.723
HMW adiponectin –1.022 0.190 –5.368 < 0.001 0.360 0.242–0.511
SE, standard error; OR, odds ratio; CI, confidence interval
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Gender-adjusted logistic regression had the diagnosis 
of T2DM as a binary variable. The level of statistical 
significance was set at 5%.
Results
Characteristics of the study population 
Age, BMI, waist circumference, blood pressure, and 
metabolic parameters in both groups are shown in 
Table I. Group A (healthy individuals) consisted of 
269 participants (143 females and 126 males) with 
a mean age of 57.5 years. In this group, the metabolic 
parameters showed normal values. The mean total 
adiponectin level was high at 10.6 mg/L. The mean 
HMW adiponectin level was 5.2 mg/L. The adiponectin 
sensitivity index was 0.49. The HOMA-IR index was 
low at 2.49, suggesting normal insulin sensitivity. The 
optimum HOMA-IR index values for identification of 
individuals with IR, as reported by epidemiological 
studies in the European population, range between 2.0 
and 3.8 [11]. Group B (diabetic patients) comprised 300 
individuals (175 females and 125 males) with a mean 
age of 59.8 years. These participants were treated with 
oral antidiabetic drugs for T2DM. In all the studied pa-
rameters, Group B was different from healthy subjects. 
Group B members had obesity (BMI 33.6), hypertension 
(145/85 mmHg), hypercholesterolaemia (5.6 mmol/L), 
hypertriglyceridaemia (2.08 mmol/L), and hyperglycae-
mia (8.4 mmol/L) at the time of measurement; sensitive 
CRP level was mildly increased (2.85 mg/L). Their total 
adiponectin level was significantly lower (5.1 mg/L) 
as compared with the healthy subjects. Similarly, the 
mean HMW adiponectin level was significantly lower 
(2.9 mg/L) than that in healthy individuals. The adi-
ponectin sensitivity index was 0.56 in Group B. Their 
HOMA-IR index was 5.43, a value typical for patients 
with IR. However, the cut-off values of HOMA-IR differ 
for different races, ages, genders, diseases, complica-
tions, etc. due to the complexity of IR [11].
Correlations between adiponectin levels and 
other indices 
Table II shows Spearman’s rank correlation coefficients 
between total or HMW adiponectin levels and the 
HOMA-IR index, insulin levels, and glucose concentra-
tions in all participants. A correlation coefficient of –0.44 
between total adiponectin levels and the HOMA-IR in-
dex values suggested a moderate monotonic correlation 
between the parameters (Figure 1), while a correlation 
coefficient of –0.39 between total adiponectin and insulin 
levels suggested a borderline weak correlation between 
the parameters. Similarly, a moderate correlation (–0.41) 
was noted between HMW adiponectin levels and the 
HOMA-IR index values (Figure 2) and a weak correlation 
(–0.33) between HMW adiponectin and insulin levels.
Predicting the risk of IR 
Results for prediction of IR risk for total adiponectin 
levels (odds ratio [OR] 0.598, 95% confidence inter-
val [CI] 0.483–0.723) and HMW adiponectin levels 
Figure 1. Correlation between total adiponectin levels [mg/L] and 
the HOMA-IR index values (r = –0.44)
Rycina 1. Współzależność między stężeniami adiponektyny 
całkowitej [mg/l] i wartościami wskaźnika HOMA-IR (r = 
 –0,44)
Figure 2. Correlation between HMW adiponectin levels [mg/L] 
and the HOMA-IR index values (r = –0.41)
Rycina 2. Współzależność między stężeniami adiponektyny 
wysokocząsteczkowej [mg/l] i wartościami wskaźnika HOMA-IR 
(r = –0,41)
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(OR 0.360, 95% CI 0.242–0.511) are presented in Table 
III. Cross-validation was used to confirm cut-offs of 
4.22 mg/L (sensitivity 0.698, specificity 0.785) and 
2.75 mg/L (sensitivity 0.830, specificity 0.660) for total and 
HMW adiponectin levels, respectively. The OR results 
showed that increased total and HMW adiponectin 
levels were a protective factor against the development 
of IR. Adiponectin levels below the indicated cut-offs 
may predict a potential risk for the development of IR. 
Discussion
IR is one of the main pathogenic mechanisms of T2DM 
and atherosclerosis that significantly contribute to mor-
bidity and mortality of the population in developed 
countries. Correlations between adiponectin levels and 
the HOMA-IR index have been consistently found in 
adults [7, 12] although age- and gender-related differ-
ences have been admitted [13]. The present study also 
showed similar correlations with the HOMA-IR index. 
The essential measure is early diagnosis of IR allowing 
interventions including both lifestyle adjustments and 
early pharmacological therapy aimed at increasing 
insulin sensitivity [6]. 
Earlier studies showed that adiponectin was strongly 
interrelated with T2DM, obesity, and inflammation. Sig-
nificant reduction of adiponectin concentrations in com-
parison with healthy controls has been reported even 
in prediabetes, which confirms the suggestion that de-
creased adiponectin levels play a role in the early stages 
of impaired glucose metabolism [14]. Impaired fasting 
glucose, impaired glucose tolerance, the HOMA-IR 
index, and serum adiponectin can be used for early 
detection of T2DM risk [15]. 
Adiponectin concentrations are indirectly associated 
with the development of inflammation. Adiponectin 
synthesis is decreased in all conditions related to 
inflammation such as IR, T2DM, or obesity [16]. In-
creased levels of CRP together with the development of 
obesity are accompanied by a decrease in adiponectin 
concentrations [17]. These observations indicate that 
the proinflammatory state and adiponectin levels are 
linked by biological mechanisms, partly independent 
of obesity [4]. In the present group of diabetic patients, 
a mild increase in CRP levels and a decrease in adi-
ponectin levels were observed. According to a Japanese 
study, CRP and HMW adiponectin levels significantly 
correlated with metabolic syndrome accompanied by 
IR, but logistic regression analysis revealed that only 
HMW adiponectin and not CRP levels were associated 
with metabolic syndrome independently of obesity [18]. 
Much attention has been paid to the role of bio-
logically active substances, such as adiponectin, in the 
pathogenesis of obesity-related disorders. With the 
development of obesity, the developing specific in-
flammatory state negatively influences adiponectin 
synthesis and may be a determining factor for the onset 
of IR. Low adiponectin concentrations are strongly cor-
related with IR present in T2DM independent of obesity 
[19–21]. Conversely, adequate adiponectin levels may 
reduce the risk for T2DM through many mechanisms, 
in particular fatty acid oxidation in the liver, increased 
peripheral glucose uptake, and stimulation of insulin 
secretion. Therefore, similar biomarkers such as adi-
ponectin may provide an important view of potential 
metabolic dysfunction in the organism and may be 
potentially used for their prognostic abilities [22]. 
Significantly reduced levels of both total and HMW 
adiponectin were apparent in diabetic patients in the 
present study as well.
Some authors have claimed that differences in in-
sulin sensitivity and degrees of IR are indicated by the 
HMW form rather than total adiponectin levels [23]. 
A decrease in HMW adiponectin levels accompanied 
by an increase in the HOMA-IR index in association 
with the development of IR was also reported in Asian 
ethnic groups in whom the relationship was even 
closer and the HOMA-IR index was even higher than 
in Europeans [24]. The present study does not suggest 
that HMW adiponectin levels are better at reflecting IR 
than total adiponectin levels. 
Obesity is associated with an imbalance of adipocy-
tokines including adiponectin. Massive weight loss is 
associated with increases in adiponectin levels [25]. The 
present study indicates that T2DM is accompanied by 
obesity. According to a study by Eglit et al., individuals 
who are obese and metabolically healthy have higher 
HMW adiponectin levels than obese persons with meta-
bolic dysfunction including IR. The association is more 
pronounced in metabolically healthy women than in 
their male counterparts. The HMW form of adiponectin 
may aid in distinguishing between metabolically healthy 
and metabolically unhealthy obese individuals [26]. 
Limitations
There are some limitations of the present study, which 
might affect the results. Total adiponectin levels in 
diabetic patients were not significantly low. Even the 
median level was not below 4 mg/L, a typical concentra-
tion for fully developed IR. This could be due to the fact 
that a majority of diabetic patients were treated with 
antidiabetic drugs, mostly metformin, in various doses 
and for various periods of time. Antidiabetic drugs 
have been shown to increase adiponectin levels [27]. 
Thus, it may be assumed that, with respect to the iden-
tified adiponectin cut-off points, diabetic patients in 
the present study treated with oral antidiabetic drugs 
might have had even lower adiponectin levels without 
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their therapy. The results might also be affected by 
the presence of various comorbidities and their treat-
ments in diabetic patients because, for example, some 
very frequently used hypolipidaemic drugs have also 
been reported to increase adiponectin levels [28]. Yet 
another limitation may be the case-control study design, 
particularly because it is difficult to accurately identify 
the temporal relationship between the development of 
IR and diagnosis of diabetes. Further research on the 
association between adiponectin levels and IR taking 
these potential confounding factors into consideration 
is needed.
Conclusions
The study results show that apart from traditional bio-
markers such as homeostatic indices or the oral glucose 
tolerance test, adiponectin levels may also be used as 
biomarkers of the presence of IR. Increased levels of 
both total adiponectin (OR 0.598) and the HMW form 
(OR 0.360) are protective factors for the development 
of IR. Cross-validation was used to confirm the cut-offs 
(total adiponectin 4.22 mg/L, HMW form 2.75 mg/L) 
signalling the development of IR. The results are valid 
for middle-aged European adults.
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